The surgery center cost a fortune to build. That was the problem, not the proof.

The subject was an owner-occupied ambulatory surgery center being financed under the SBA 504 program, with the occupying physician group using the building for its own surgical procedures. The sponsor's case rested on the build: a high cost per square foot for the surgical fit-out, a value that the cost supported, and a facility clearly worth what it took to construct.

The 504 program finances owner-occupied real estate, and because a surgery center is a special-purpose property, the SBA's process requires a going-concern appraisal by a qualified appraiser that allocates value separately among the land, the building, the specialized equipment, and the intangible business value — and a heavier equity injection than a generic building would carry. The question the file turned on was not what the facility cost but what the building would be worth to a different user: what a lender could recover if the surgery center closed and the building had to be sold or leased to someone who did not perform surgery.

The intuitive way to value an expensive, purpose-built facility is its cost: confirm the high build cost per square foot for the surgical fit-out, take an appraisal that reflects it, and read a well-supported value off what the facility took to construct. On that logic the deal looked strong — a costly, specialized build, a value the cost confirmed, a facility plainly worth its construction. The cost did the persuading.

It was also treating the cost of the specialized build as if it were recoverable value, when the very features that made the surgery center expensive are the features a different tenant would not value at all.

A special-purpose medical facility is worth far more to the operator who built it than to the next user who has to take over the building, so the as-built cost and the collateral value are different numbers — and the features that drove the cost up are often the features that drive the re-tenant value down. An ambulatory surgery center carries an expensive, highly specialized fit-out: the operating rooms, the medical gas systems, the specialized plumbing, power, and air handling, the surgical-grade finishes. Those improvements are a large share of what the building cost — but they are not a share the next tenant necessarily values. A different medical specialty may need a completely different layout; a non-surgical medical user values the operating rooms at close to nothing; and a non-medical user values the whole specialized build at close to nothing and may have to pay to remove it. So if the surgery center closes, the building does not re-tenant at its as-built value — it re-tenants at its "dark value," the value to a generic or different user, which for a purpose-built surgical facility can sit far below what it cost to build, and the backfill is slow and costly because the pool of users who want exactly that building is thin. The cost confirms what the operator spent; the collateral analysis has to capture what a different user would pay — because that is what the lender holds. That gap is precisely why the SBA treats a surgery center as special-purpose, requires the going-concern appraisal to break out the land, building, equipment, and intangible value separately, and holds the equity injection higher: the specialized and intangible value is real while the surgery center operates and thin if it stops.

The inflection is that the high cost was real and was not collateral — the loan was an operating-business credit secured by a special-purpose building, and the bankable question was the building's value to a different user, not its cost to the one who built it. Re-analyzed with the value separated into the land, the generic building shell, the specialized surgical equipment and improvements, and the intangible business value, the deal's collateral profile came into focus: the share genuinely recoverable from the real estate to a different user was smaller than the as-built cost implied, the specialized improvements would not carry their cost to the next tenant, and the loan had to be sized to that dark-value reality and the heavier equity the special-purpose property requires. But the same analysis is what made the deal financeable on the right terms: the 504 program finances owner-occupied special-purpose property precisely because the occupying business's cash flow services the loan, so a sound surgical practice in a defensible facility supports the credit — once the collateral is understood as the building to a different user, the equity cushion is sized to the special-purpose risk, and the loan is underwritten to the practice that occupies it. The bankable analysis was the dark value and the practice credit behind it, not the as-built cost. The relevant analysis was what the building is worth to a different user, not what it cost the one who built it.

Value separated into its components. The as-built value was broken out into the land, the generic building shell, the specialized surgical equipment and improvements, and the intangible business value, so the analysis distinguished what the facility cost from what the building would be worth to someone else.

Dark value, not as-built cost. The building's value to a generic or different user — its dark value — was estimated against the thin pool of users who would want a purpose-built surgical facility, so the collateral reflected what a lender could recover if the surgery center closed rather than what it cost to construct.

The specialized improvements' transferability. The specialized improvements were tested for whether the next user would value them — operating rooms, medical gas, surgical plumbing, power, and air handling built to one practice's procedures — surfacing how much of the build cost would not carry to a different tenant, and what removal a non-medical user might require.

Backfill time and cost. The time and cost to re-tenant the facility to a different user were examined, because a thin user pool makes a special-purpose building slow and expensive to backfill, which is part of the collateral's real value.

Special-purpose treatment and equity cushion. The deal was structured against the SBA's special-purpose treatment — the going-concern appraisal allocating value separately, performed by the appraiser, and the heavier equity injection — so the financing reflected the dark-value risk rather than a generic building's terms.

The practice credit behind the building. The occupying surgical practice's cash flow and debt-service capacity were analyzed as the source of repayment, because a 504 loan on a special-purpose building is an operating-business credit secured by real estate, and a sound practice is what supports a building a passive investor would not take.

The credit file replaced an as-built cost with a collateral analysis built on the building's value to a different user and explained why an expensive facility was secured by an asset worth far less to anyone who did not perform surgery. The analysis separated the land, the shell, the specialized equipment, and the intangible value, estimated the dark value and the backfill, and tied repayment to the occupying practice's cash flow. The SBA and the lender sized the 504 loan to the dark-value reality and the special-purpose equity injection, and the appraiser's going-concern appraisal allocated the components separately. The feasibility analysis answered the program's expectation by evaluating what the building would be worth to a different user and what practice supported it, which is where special-purpose medical credits are most often misjudged.

The 504 financing closed sized to the building's dark value and a heavier equity cushion, and underwritten to the practice that occupies it — not to an as-built cost the collateral could not stand behind if the surgery center closed. The inflection was not that the facility was weak; it was a sound, busy surgical practice. It was that the features that made the surgery center expensive are the features the next user would not pay for, so the collateral behind the loan is the building to a different user, and the bankable deal was the one underwritten to the dark value and the practice credit rather than to the as-built cost.

• 01As-built cost is not collateral value. A special-purpose facility is worth far more to the operator who built it than to the next user who must take over the building, and the loan is secured by the building.
• 02The features that raise cost can lower re-tenant value. Operating rooms, medical gas, and specialized systems are a large share of a surgery center's cost and a small share of what a different user values — and a non-medical user may pay to remove them.
• 03Dark value governs the downside. If the surgery center closes, the building re-tenants at its value to a generic or different user — often far below as-built cost — and the backfill is slow because the user pool is thin.
• 04Size to the dark value and the practice credit. The SBA treats a surgery center as special-purpose with a heavier equity cushion for this reason; a 504 loan is an operating-business credit secured by real estate, and the bankable deal is underwritten to the building's value to a different user and the practice behind it.